In Brief: Myriad Genetics Laboratories
This article was originally published in The Gray Sheet
Executive Summary
Myriad Genetics Laboratories: Begins long-term study with the American College of Surgeons to evaluate outcomes of patients undergoing BRCA1 genetic analysis for breast and ovarian cancer susceptibility. The ACS-Myriad BRCA1 Longitudinal Study (AMBLS) will use Myriad's BRACAone genetic analysis test, which is slated for full commercial launch later this year ("The Gray Sheet" July 22, In Brief), and the firm's "multi-center, patient database to obtain mutation incidence and clinical data." The "major questions" to be addressed by the study include: "which BRCA1 mutations are strongly penetrant (have a strong correlation to the risk of getting the disease); and what is the likely clinical outcome after medical and surgical intervention"...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.